Compared to studies in which treatment began at weeks 3 or 4 of CCl4 injection or weeks 6 to 8 of high-fat diet feeding, we began injecting PRL at later phases of CCl4 or nonalcoholic steatohepatitis (NASH) model development. This evidence concerns the gene PRL and metabolic dysfunction-associated steatohepatitis.